{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:53:57Z","timestamp":1787165637226,"version":"build-2736575974"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203839\/A\/16\/Z"],"award-info":[{"award-number":["203839\/A\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lateral flow urine lipoarabinomannan (LAM) tests could offer important new opportunities for the early detection of tuberculosis (TB). The currently licensed LAM test, Alere Determine TB LAM Ag (\u2018LF-LAM\u2019), performs best in the sickest people living with HIV (PLHIV). However, the technology continues to improve, with newer LAM tests, such as Fujifilm SILVAMP TB LAM (\u2018SILVAMP-LAM\u2019) showing improved sensitivity, including amongst HIV-negative patients. It is important to anticipate the epidemiological impact that current and future LAM tests may have on TB incidence and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>Concentrating on South Africa, we examined the impact that widening LAM test eligibility would have on TB incidence and mortality. We developed a mathematical model of TB transmission to project the impact of LAM tests, distinguishing \u2018current\u2019 tests (with sensitivity consistent with LF-LAM), from hypothetical \u2018future\u2019 tests (having sensitivity consistent with SILVAMP-LAM). We modelled the impact of both tests, assuming full adoption of the 2019 WHO guidelines for the use of these tests amongst those receiving HIV care. We also simulated the hypothetical deployment of future LAM tests for all people presenting to care with TB symptoms, not restricted to PLHIV. Our model projects that 2,700,000 (95% credible interval [CrI] 2,000,000\u20133,600,000) and 420,000 (95% CrI 350,000\u2013520,000) cumulative TB incident cases and deaths, respectively, would occur between 2020 and 2035 if the status quo is maintained. Relative to this comparator, current and future LAM tests would respectively avert 54 (95% CrI 33\u201386) and 90 (95% CrI 55\u2013145) TB deaths amongst inpatients between 2020 and 2035, i.e., reductions of 5% (95% CrI 4%\u20136%) and 9% (95% CrI 7%\u201311%) in inpatient TB mortality. This impact in absolute deaths averted doubles if testing is expanded to include outpatients, yet remains &lt;1% of country-level TB deaths. Similar patterns apply to incidence results. However, deploying a future LAM test for all people presenting to care with TB symptoms would avert 470,000 (95% CrI 220,000\u2013870,000) incident TB cases (18% reduction, 95% CrI 9%\u201329%) and 120,000 (95% CrI 69,000\u2013210,000) deaths (30% reduction, 95% CrI 18%\u201344%) between 2020 and 2035. Notably, this increase in impact arises largely from diagnosis of TB amongst those with HIV who are not yet in HIV care, and who would thus be ineligible for a LAM test under current guidelines. Qualitatively similar results apply under an alternative comparator assuming expanded use of GeneXpert MTB\/RIF (\u2018Xpert\u2019) for TB diagnosis. Sensitivity analysis demonstrates qualitatively similar results in a setting like Kenya, which also has a generalised HIV epidemic, but a lower burden of HIV\/TB coinfection. Amongst limitations of this analysis, we do not address the cost or cost-effectiveness of future tests. Our model neglects drug resistance and focuses on the country-level epidemic, thus ignoring subnational variations in HIV and TB burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that LAM tests could have an important effect in averting TB deaths amongst PLHIV with advanced disease. However, achieving population-level impact on the TB epidemic, even in high-HIV-burden settings, will require future LAM tests to have sufficient performance to be deployed more broadly than in HIV care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003466","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T13:26:32Z","timestamp":1607693192000},"page":"e1003466","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-6111","authenticated-orcid":true,"given":"Saskia","family":"Ricks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7216-7067","authenticated-orcid":true,"given":"Claudia M.","family":"Denkinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6136-206X","authenticated-orcid":true,"given":"Samuel G.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-0424","authenticated-orcid":true,"given":"Timothy B.","family":"Hallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-150X","authenticated-orcid":true,"given":"Nimalan","family":"Arinaminpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"pmed.1003466.ref001","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S1473-3099(18)30111-7","article-title":"Tuberculosis: advances and challenges in development of new diagnostics and biomarkers","volume":"18","author":"G Walzl","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pmed.1003466.ref002","volume-title":"Global tuberculosis report 2019","author":"World Health Organization","year":"2019"},{"key":"pmed.1003466.ref003","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1473-3099(06)70602-8","article-title":"Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review","volume":"6","author":"KR Steingart","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"pmed.1003466.ref004","first-page":"CD009593","article-title":"Xpert\u00ae MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults","volume":"2014","author":"KR Steingart","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"pmed.1003466.ref005","doi-asserted-by":"crossref","first-page":"e1001064","DOI":"10.1371\/journal.pmed.1001064","article-title":"GeneXpert\u2014a game-changer for tuberculosis control?","volume":"8","author":"CA Evans","year":"2011","journal-title":"PLoS Med"},{"key":"pmed.1003466.ref006","doi-asserted-by":"crossref","first-page":"S1159","DOI":"10.1093\/infdis\/jir411","article-title":"Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis","volume":"204","author":"SD Lawn","year":"2011","journal-title":"J Infect Dis"},{"key":"pmed.1003466.ref007","volume-title":"High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting","author":"World Health Organization","year":"2014"},{"key":"pmed.1003466.ref008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12916-017-0822-8","article-title":"Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort","volume":"15","author":"SD Lawn","year":"2017","journal-title":"BMC Med"},{"key":"pmed.1003466.ref009","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1473-3099(19)30001-5","article-title":"Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study","volume":"19","author":"T Broger","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pmed.1003466.ref010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(18)31267-4","article-title":"Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial","volume":"392","author":"A Gupta-Wright","year":"2018","journal-title":"Lancet"},{"key":"pmed.1003466.ref011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2334-12-103","article-title":"Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review","volume":"12","author":"SD Lawn","year":"2012","journal-title":"BMC Infect Dis"},{"key":"pmed.1003466.ref012","first-page":"CD011420","article-title":"Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV: an updated systematic review","volume":"10","author":"S Bjerrum","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"pmed.1003466.ref013","volume-title":"Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV","author":"World Health Organization","year":"2019"},{"key":"pmed.1003466.ref014","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1172\/JCI140461","article-title":"Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients","volume":"130","author":"T Broger","year":"2020","journal-title":"J Clin Invest"},{"key":"pmed.1003466.ref015","doi-asserted-by":"crossref","first-page":"eaal2807","DOI":"10.1126\/scitranslmed.aal2807","article-title":"Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity","volume":"9","author":"L Paris","year":"2017","journal-title":"Sci Transl Med"},{"key":"pmed.1003466.ref016","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00285-008-0177-z","article-title":"Modeling the joint epidemics of TB and HIV in a South African township","volume":"57","author":"N Baca\u00ebr","year":"2008","journal-title":"J Math Biol"},{"key":"pmed.1003466.ref017","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1073\/pnas.0600349103","article-title":"Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations","volume":"103","author":"T Cohen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pmed.1003466.ref018","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"E Vynnycky","year":"1997","journal-title":"Epidemiol Infect"},{"key":"pmed.1003466.ref019","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(98)03199-7","article-title":"Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy","volume":"352","author":"C Dye","year":"1998","journal-title":"Lancet"},{"key":"pmed.1003466.ref020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJM199201233260404","article-title":"An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms","volume":"326","author":"CL Daley","year":"1992","journal-title":"N Engl J Med"},{"key":"pmed.1003466.ref021","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.200909-1355OC","article-title":"Revisiting rates of reactivation tuberculosis: a population-based approach","volume":"182","author":"CR Horsburgh","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"pmed.1003466.ref022","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(02)08904-3","article-title":"Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study","volume":"359","author":"M Badri","year":"2002","journal-title":"Lancet"},{"key":"pmed.1003466.ref023","doi-asserted-by":"crossref","first-page":"e45724","DOI":"10.1371\/journal.pone.0045724","article-title":"The rate of sputum smear-positive tuberculosis after treatment default in a high-burden setting: a retrospective cohort study","volume":"7","author":"FM Marx","year":"2012","journal-title":"PLoS ONE"},{"key":"pmed.1003466.ref024","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/323784","article-title":"Relapse in persons treated for drug\u2010susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City","volume":"33","author":"CR Driver","year":"2001","journal-title":"Clin Infect Dis"},{"key":"pmed.1003466.ref025","doi-asserted-by":"crossref","first-page":"e1000146","DOI":"10.1371\/journal.pmed.1000146","article-title":"Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis","volume":"6","author":"D Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"pmed.1003466.ref026","first-page":"556","article-title":"Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme","volume":"9","author":"A Thomas","year":"2005","journal-title":"South India. Int J Tuberc Lung Dis"},{"key":"pmed.1003466.ref027","doi-asserted-by":"crossref","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"EW Tiemersma","year":"2011","journal-title":"PLoS ONE"},{"key":"pmed.1003466.ref028","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis","volume":"54","author":"JR Andrews","year":"2012","journal-title":"Clin Infect Dis"},{"key":"pmed.1003466.ref029","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/cid\/cir898","article-title":"AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in C\u00f4te d\u2019Ivoire","volume":"54","author":"X Anglaret","year":"2012","journal-title":"Clin Infect Dis"},{"key":"pmed.1003466.ref030","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0140-6736(06)69117-4","article-title":"Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study","volume":"368","author":"M Badri","year":"2006","journal-title":"Lancet"},{"key":"pmed.1003466.ref031","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0000000000001437","article-title":"Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection","volume":"31","author":"TD Mangal","year":"2017","journal-title":"AIDS"},{"key":"pmed.1003466.ref032","doi-asserted-by":"crossref","first-page":"S702","DOI":"10.1093\/infdis\/jix335","article-title":"The South African tuberculosis care cascade: estimated losses and methodological challenges","volume":"216","author":"P Naidoo","year":"2017","journal-title":"J Infect Dis"},{"key":"pmed.1003466.ref033","doi-asserted-by":"crossref","first-page":"e021111","DOI":"10.1136\/bmjopen-2017-021111","article-title":"Linkage to care among adults being investigated for tuberculosis in South Africa: pilot study of a case manager intervention","volume":"8","author":"N Maraba","year":"2018","journal-title":"BMJ Open"},{"key":"pmed.1003466.ref034","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s10096-014-2198-4","article-title":"A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community","volume":"33","author":"HD Geldenhuys","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"pmed.1003466.ref035","first-page":"192","article-title":"Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB\/RIF: a prospective cohort","volume":"13","author":"SD Lawn","year":"2015","journal-title":"South Africa. BMC Med"},{"key":"pmed.1003466.ref036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2018.08.005","article-title":"Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV","volume":"75","author":"TH Boyles","year":"2018","journal-title":"Int J Infect Dis"},{"key":"pmed.1003466.ref037","unstructured":"AIDSinfo. Trend of new HIV infections. Geneva: Joint United Programme on HIV\/AIDS; 2019 [cited 2019 Oct 8]. Available from: http:\/\/aidsinfo.unaids.org."},{"key":"pmed.1003466.ref038","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1038\/s41598-017-09895-7","article-title":"Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays","volume":"7","author":"AD Kerkhoff","year":"2017","journal-title":"Sci Rep"},{"key":"pmed.1003466.ref039","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/QAI.0b013e31827e8785","article-title":"Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa","volume":"62","author":"G Meyer-Rath","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1003466.ref040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/QAI.0000000000000436","article-title":"Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis","volume":"68","author":"PK Drain","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1003466.ref041","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/ijerph15040729","article-title":"Measuring quality gaps in TB screening in South Africa using standardised patient analysis","volume":"15","author":"CS Christian","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"pmed.1003466.ref042","doi-asserted-by":"crossref","first-page":"30314","DOI":"10.3402\/gha.v9.30314","article-title":"Prospects for HIV control in South Africa: a model-based analysis","volume":"9","author":"L Johnson","year":"2016","journal-title":"Glob Health Action"},{"key":"pmed.1003466.ref043","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3018(18)30104-8","article-title":"Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey","volume":"5","author":"A Kharsany","year":"2018","journal-title":"Lancet HIV"},{"issue":"Suppl 3","key":"pmed.1003466.ref044","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/09540121.2016.1164808","article-title":"Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa","volume":"28","author":"S Boyer","year":"2016","journal-title":"AIDS Care"},{"key":"pmed.1003466.ref045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12889-018-5208-0","article-title":"Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey","volume":"18","author":"H Huerga","year":"2018","journal-title":"BMC Public Health"},{"key":"pmed.1003466.ref046","doi-asserted-by":"crossref","first-page":"4","DOI":"10.11604\/pamj.2015.22.4.6075","article-title":"Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa","volume":"22","author":"A d\u2019Elia","year":"2015","journal-title":"Pan Afr Med J"},{"key":"pmed.1003466.ref047","doi-asserted-by":"crossref","first-page":"ofx167","DOI":"10.1093\/ofid\/ofx167","article-title":"Clinic-based urinary lipoarabinomannan as a biomarker of clinical disease severity and mortality among antiretroviral therapy-naive human immunodeficiency virus-infected adults in South Africa","volume":"4","author":"P Drain","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"pmed.1003466.ref048","doi-asserted-by":"crossref","first-page":"e0204020","DOI":"10.1371\/journal.pone.0204020","article-title":"Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa","volume":"13","author":"AT Brennan","year":"2018","journal-title":"PLoS ONE"},{"key":"pmed.1003466.ref049","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10461-018-2222-2","article-title":"Timing and predictors of initiation on antiretroviral therapy among newly-diagnosed HIV-infected persons in South Africa","volume":"23","author":"A Larsen","year":"2019","journal-title":"AIDS Behav"},{"key":"pmed.1003466.ref050","doi-asserted-by":"crossref","first-page":"e0195127","DOI":"10.1371\/journal.pone.0195127","article-title":"Attrition when providing antiretroviral treatment at CD4 counts >500cells\/\u03bcL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.","volume":"13","author":"P Bock","year":"2018","journal-title":"PLoS ONE"},{"key":"pmed.1003466.ref051","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1007\/s10461-016-1442-6","article-title":"Depression and engagement in care among newly diagnosed HIV-infected adults in Johannesburg","volume":"21","author":"R Cholera","year":"2017","journal-title":"South Africa. AIDS Behav"},{"key":"pmed.1003466.ref052","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000000755","article-title":"Brief report: does most mortality in patients on ART occur in care or after lost to follow-up? Evidence from the Themba Lethu Clinic, South Africa","volume":"70","author":"E Budgell","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1003466.ref053","doi-asserted-by":"crossref","first-page":"e0148546","DOI":"10.1371\/journal.pone.0148546","article-title":"The high cost of HIV-positive inpatient care at an urban hospital in Johannesburg, South Africa","volume":"11","author":"LC Long","year":"2016","journal-title":"PLoS ONE"},{"key":"pmed.1003466.ref054","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2307\/3318737","article-title":"An adaptive metropolis algorithm","volume":"7","author":"H Haario","year":"2001","journal-title":"Bernoulli"},{"key":"pmed.1003466.ref055","first-page":"150","article-title":"What if they don\u2019t have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis","volume":"68","author":"RMGJ Houben","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pmed.1003466.ref056","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0140-6736(10)60359-5","article-title":"Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice","volume":"375","author":"RS Wallis","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 2","key":"pmed.1003466.ref057","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/infdis\/jiu803","article-title":"Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects","volume":"211","author":"M Pai","year":"2015","journal-title":"J Infect Dis"},{"key":"pmed.1003466.ref058","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(19)30024-8","article-title":"Building a tuberculosis-free world: the Lancet Commission on tuberculosis","volume":"393","author":"MJA Reid","year":"2019","journal-title":"Lancet"},{"key":"pmed.1003466.ref059","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1016\/S2214-109X(18)30436-4","article-title":"Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study","volume":"7","author":"KP Reddy","year":"2019","journal-title":"Lancet Glob Health"},{"key":"pmed.1003466.ref060","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/aje\/kwz038","article-title":"Estimating the impact of tuberculosis case detection in constrained health systems: an example of case-finding in South Africa","volume":"188","author":"T Sumner","year":"2019","journal-title":"Am J Epidemiol"},{"key":"pmed.1003466.ref061","doi-asserted-by":"crossref","first-page":"e0209320","DOI":"10.1371\/journal.pone.0209320","article-title":"Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa","volume":"14","author":"P Hippner","year":"2019","journal-title":"PLoS ONE"},{"key":"pmed.1003466.ref062","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1473-3099(15)00147-4","article-title":"Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004\u201312: a time series analysis.","volume":"15","author":"A Nanoo","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"pmed.1003466.ref063","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(13)70008-2","article-title":"Advances in tuberculosis diagnostics: the Xpert MTB\/RIF assay and future prospects for a point-of-care test","volume":"13","author":"SD Lawn","year":"2013","journal-title":"Lancet Infect Dis"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T13:27:00Z","timestamp":1607693220000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003466"}},"subtitle":[],"editor":[{"given":"Amitabh Bipin","family":"Suthar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003466","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}